Filtered By:
Therapy: Chemotherapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 62 results found since Jan 2013.

The Incident Ocular Diseases Related to Chemotherapy in Cancer Patients are Associated with Increasing Risk of Incident Stroke
CONCLUSIONS: Incident ocular diseases related to chemotherapy were associated with a significantly higher risk of stroke.PMID:37229341 | PMC:PMC10203719 | DOI:10.6515/ACS.202305_39(3).20221005A
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Kai-Chun Cheng Hung-Pin Tu Tsung-Hsien Lin Kai-Hung Cheng Source Type: research

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Intraocular medulloepithelioma clinical features and management of 11 cases
CONCLUSIONS: Initial misdiagnosis, delay in diagnosis and subsequent misdirected management is not uncommon in medulloepithelioma. The presence of multiple cysts in the tumour and retrolental neoplastic cyclitic membrane detected by UBM can offer certain information. Selective intra-arterial melphalan may prevent further tumour growth, but longer follow-up is necessary until treatment efficacy is fully evaluated.PMID:36997291 | DOI:10.1136/bjo-2022-322449
Source: The British Journal of Ophthalmology - March 30, 2023 Category: Opthalmology Authors: Xiuqian Yi Fengxi Meng Yingwen Bi Lin He Jiang Qian Kang Xue Source Type: research

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bilateral Morgagnian Cataract Post Neoadjuvant Chemotherapy for Oral Carcinoma- A Potentially Blinding Sequelae
This report highlights a rare case of bilateral Morgagnian cataract following neoadjuvant chemotherapy given for an oral cavity malignancy. A 65-year-old female presented with bilateral reduced visual acuity secondary to Morgagnian cataract with normal fundus. The patient underwent a successful cataract surgery in right eye preventing the eye from developing devastating sequelae like phacomorphic glaucoma, lens subluxation, or aphakia post-cataract surgery. The oncosurgeon, oncologist, and ophthalmologist should have a close liaison to prevent, diagnose, and treat these rare sequelae which could be potentially blinding.
Source: Indian Journal of Surgical Oncology - July 8, 2022 Category: Cancer & Oncology Source Type: research

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review
Conclusion: According to our observations, we recommend that the utmost care should be taken when considering PPV for the treatment of activated RB. When weighing the risk of tumor recurrence and metastasis, PPV is not suitable for routine treatment. It is necessary to fully grasp the operative indications and strictly observe operation specifications, which includes close postoperative follow-up.PMID:34747279 | PMC:PMC8573478 | DOI:10.1177/15330338211048634
Source: Technology in Cancer Research and Treatment - November 8, 2021 Category: Cancer & Oncology Authors: Lu Li Tao He Yu Su Li Wu Changzheng Chen Source Type: research

Progressive Dyspnea With Recurrent Pneumothoraces
Chest. 2021 Aug;160(2):e209-e215. doi: 10.1016/j.chest.2021.03.052.ABSTRACTA 34-year-old previously healthy man of Korean descent (height, 174 cm; weight, 47.4 kg) demonstrated dyspnea with cough and chest tightness. The patient had no relevant occupational exposures and no history of illicit drug or tobacco use. His medical history was notable for chronic sinus tachycardia of undetermined cause, hypertension, gout, glaucoma of the right eye, and a remote history of an intracranial malignancy 24 years prior treated with unspecified chemotherapy, craniotomy, and ventriculoperitoneal shunt placement. His active medications i...
Source: Chest - August 9, 2021 Category: Respiratory Medicine Authors: Kai L Homer Jake Mandziuk Alim Hirji James Barrie Steven R Meyer Eric Y L Wong Lakshmi Puttagunta Kieran M Halloran Source Type: research

Case Report: Steroid-induced Ocular Hypertension in a 6-year-old Boy
CONCLUSIONS This case reminds eye care providers to be aware of the potential ocular hypertensive response to systemic steroid treatment and the importance of establishing early monitoring. With the emergence of multisystem inflammatory syndrome in children during the current COVID-19 pandemic, eye care providers may encounter more pediatric patients on systemic corticosteroid treatment than previously and should adjust their examinations appropriately.
Source: Optometry and Vision Science - August 1, 2021 Category: Opthalmology Tags: REPORTS Source Type: research

SRp20: A potential therapeutic target for human tumors
Pathol Res Pract. 2021 Apr 14;224:153444. doi: 10.1016/j.prp.2021.153444. Online ahead of print.ABSTRACTAs an important member of SR protein family, SRp20 plays a crucial role in alternative splicing. It not only participates in cell cycle regulation, export of mRNA, cleaving of primary microRNAs, homologous recombination-mediated DNA repair, cellular senescence and apoptosis, but also gets involved in the integrity and pluripotency of genome. Alternative splicing maintains a strict balance in the body to ensure the normal physiological function of cells. Once the balance is broken, diseases, even tumors, will follow. Thro...
Source: Pathology, Research and Practice - June 14, 2021 Category: Pathology Authors: Han Wang Yanxia Jiang Source Type: research